Format

Send to

Choose Destination
J Radioanal Nucl Chem. 2015;305(1):9-12. Epub 2015 Apr 1.

Future U.S. supply of Mo-99 production through fission based LEU/LEU technology.

Author information

1
Coquí RadioPharmaceuticals Corp., 1172 South Dixie Hwy., Suite 335, Coral Gables, FL 33146 USA.

Abstract

Coquí RadioPharmaceuticals Corp. (Coquí) has the goal of establishing a medical isotope production facility for securing a continuous domestic supply of the radioisotope molybdenum-99 for U.S. citizens. Coquí will use an LEU/LEU proven and implemented open pool, light-water, 10 MW, reactor design. The facility is being designed with twin reactors for reliability an on-site hot lab chemical processing and a waste conditioning area and a possible generator producing radio-chemistry lab. Coquí identified a 25 acre site adjacent to an existing industrial park in northern central Florida. This land was gifted and transferred to Coquí by the University of Florida Foundation. We are in the process of developing licensing documents related to the facility. The construction permit application for submission to the U.S. Nuclear Regulatory Commission is currently being prepared. Submission is scheduled for mid to late 2015. Community reaction to the proposed development has been positive. We expect to create 220 permanent jobs and we have an anticipated to be operational by 2020.

KEYWORDS:

Diagnosis; Molybdenum-99; Nuclear medicine; Production through fission based LEU/LEU; Technetium-99; U.S. supply of Mo-99

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center